The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation  

作　　者：Hiroshi Hongo Takeo Kosaka Kohei Nakamura Shuji Mikami Hiroshi Nishihara Mototsugu Oya 

机构地区：[1]Department of Urology,Keio University School of Medicine,Japan [2]Genomics Unit,Keio Cancer Center,Keio University School of Medicine,Japan [3]Department of Diagnostic Pathology,Keio University Hospital,Japan

出　　处：《Asian Journal of Urology》2022年第4期480-482,共3页亚洲泌尿外科杂志（英文）

基　　金：This study was supported in part by Grants-in-Aid for Sci-entific Research(#17K16813 to Hongo H and#17K11158 E.20H03817 to Kosaka T)from the Ministry of Education,Culture,Sports,Science,and Technology of Japan;The study was supported in part by research grant to Kosaka T from the Takeda Science Foundation,Japan.

摘　　要：Dear editor:Intraductalcarcinomaoftheprostate(IDC-P)ischaracterized by expansive growth of cancer cells in normal prostatic ducts with basal cell layer and associated with high grade invasive prostate cancer(PCa).However,the molecular profile or clinical character of IDC-P in progressive castration-resistant PCa(CRPC)was not fully characterized yet.

关 键 词：CANCER clinical PROSTATIC 

分 类 号：R737.25[医药卫生—肿瘤]